Pyrazin-2-Amine HPK1 Inhibitors for Selective Antitumor Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new Hematopoietic Progenitor Kinase 1 (HPK1) kinase inhibitors to enhance antitumor immunity and treat cancer effectively.
Innovation Solution
Development of 3-[(1H-pyrazol-4-yl)oxy]pyrazin-2-amine compounds that modulate HPK1 activity, inhibiting its function to enhance T cell activation and immune response against tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing HPK1 inhibitors (benzoimidazoles, pyrazolopyrmidines, pyrazolopyridones, pyrazolopyridines, pyrrolopyridines) are used, then HPK1 kinase activity is inhibited, but there is insufficient antitumor efficacy or need for new compounds with improved properties
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of HPK1 inhibitors through varying substituents (R1, R2, R3, R4, R5, R6, R7, R8, R9, Ra, Rb) on the pyrazine core framework. This allows optimization of kinase inhibition potency and antitumor efficacy while maintaining the basic mechanism of action, thereby resolving the need for new compounds with improved properties
2Reliability
If HPK1 kinase activity is inhibited to enhance T cell activation, then immune response against tumors is enhanced, but selectivity and off-target effects need to be controlled
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at different positions on the pyrazine ring system. Each substituent (R1-R9, Ra, Rb) can be independently optimized to enhance binding affinity for HPK1 while minimizing interactions with off-target kinases, thus achieving selective inhibition that enhances immune response without unwanted side effects
Data Source
AI summary
Disclosed herein is 3- [ (1H-pyrazol-4-yl) oxy] pyrazin-2-amine compounds of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of modulating, e.g., inhibiting or treating HPK1 related disorders or diseases including cancer by using the compound disclosed herein